CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment

被引:180
作者
Patten, Piers E. M. [1 ]
Buggins, Andrea G. S. [1 ]
Richards, Julie [1 ]
Wotherspoon, Andrew [2 ]
Salisbury, Jon [3 ]
Mufti, Ghulam J. [1 ]
Hamblin, Terry J. [1 ]
Devereux, Stephen [1 ]
机构
[1] Kings Coll London, Dept Haematol & Mol Med, Rayne Inst, London SE5 9NU, England
[2] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England
[3] Kings Coll London, Dept Histopathol, London WC2R 2LS, England
关键词
D O I
10.1182/blood-2007-08-108605
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease with a highly variable outcome. The prognosis of patients with CLL may be predicted using a number of biomarkers, including the level of CD38 expression at the leukemic cell surface. This study investigates the hypothesis that CD38 expression by CLL cells reflects interactions with nonmalignant cells within pseudofollicles in secondary lymphoid tissue where tumor cell proliferation is thought to occur. CD38 expression is higher in tissues that contain pseudofollicles compared with those that do not. In addition, we show that CD38 expression in CLL is dynamic, changes in response to contact with activated CD4(+) T cells, and identifies cells that are primed to proliferate. Finally, we demonstrate close contact between activated CD4+ T cells and proliferating tumor in primary patient tissue. Proliferating tumor cells in lymph nodes express CD38, which is in turn associated with an increased number of CD31(+) vascular endothelial cells. Although the factors resulting in colocalization of tumor, T cells, and endothelium remain unclear, the existence of these cellular clusters may provide an explanation for the association between CD38 expression and adverse outcome in CLL and suggests novel therapeutic targets.
引用
收藏
页码:5173 / 5181
页数:9
相关论文
共 45 条
  • [1] Aguayo A, 2000, BLOOD, V96, P768
  • [2] ALESSIO M, 1990, J IMMUNOL, V145, P878
  • [3] Immunophenotype does not correlate with lymph node histology in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Asplund, SL
    McKenna, RW
    Howard, MS
    Kroft, SH
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (05) : 624 - 629
  • [4] BENEZRA J, 1989, BLOOD, V73, P579
  • [5] B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle
    Bennett, Fiona
    Rawstron, Andy
    Plummer, Marieth
    de Tute, Ruth
    Moreton, Paul
    Jack, Andrew
    Hillmen, Peter
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (04) : 600 - 604
  • [6] BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
  • [7] 2-V
  • [8] Lymph node histology in typical and atypical chronic lymphocytic leukemia
    Bonato, M
    Pittaluga, S
    Tierens, A
    Criel, A
    Verhoef, G
    Wlodarska, I
    Vanutysel, L
    Michaux, L
    Vandekerckhove, P
    Van den Berghe, H
    De Wolf-Peeters, C
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (01) : 49 - 56
  • [9] Acquired CD40-ligand deficiency in chronic lymphocytic leukemia
    Cantwell, M
    Hua, T
    Pappas, J
    Kipps, TJ
    [J]. NATURE MEDICINE, 1997, 3 (09) : 984 - 989
  • [10] Conversion of CD38 and/or myeloid-associated marker expression status during the course of B-CLL: association with a change to an aggressive clinical course
    Chang, CC
    Cleveland, RP
    [J]. BLOOD, 2002, 100 (03) : 1106 - 1106